Updated Jul 16, 2026
Baroldi Joseph has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $6.29M.

Joseph Baroldi is the Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals, a leader in antisense technology for drug development. He has been involved in various roles within the company, contributing to its focus on innovative treatments for a range of diseases.
| Role | EVP, Chief Business Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-30 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 5.6K | $80.16 | $452K |
| 2026-06-30 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 1.8K | $32.60 | $58K |
| 2026-06-30 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 3.9K | $56.78 | $220K |
| 2026-04-17 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 5.6K | $74.56 | $419K |
| 2026-04-17 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 10.8K | $0.00 | |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 201 | $80.00 | $16K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 201 | $32.60 | $7K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 238 | $80.00 | $19K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 238 | $56.78 | $14K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 36 | $81.01 | $3K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 2.1K | $80.41 | $168K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 879 | $32.60 | $29K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise [10b5-1] | 820 | $56.78 | $47K |
| 2026-03-05 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale [10b5-1] | 4.1K | $79.36 | $325K |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 5.3K | $82.96 | $439K |
| 2026-02-03 | IONS | IONIS PHARMACEUTICALS INC | A — Grant or award | 10.3K | $0.00 | |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 1.1K | $75.78 | $87K |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 2.9K | $0.00 | |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | S — Open-market sale | 6.9K | $75.75 | $523K |
| 2026-01-21 | IONS | IONIS PHARMACEUTICALS INC | M — Option exercise | 17.0K | $0.00 |
Joseph Baroldi is the Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals, a leader in antisense technology for drug development. He has been involved in various roles within the company, contributing to its focus on innovative treatments for a range of diseases.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($6.29M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Baroldi Joseph profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.